Patient preferences in severe COPD and asthma: A comprehensive literature review

International Journal of COPD

Volumn 10, Issue , 2015, Pages 739-744

  Bereza, Basil G ^a   Nielsen, Anders Troelsgaard ^b   Valgardsson, Sverrir ^c   Hemels, Michiel E H ^b   Einarson, Thomas R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Janssen Pharma A/S   (Denmark)

^c Janssen Cilag   (Norway)

Author keywords

Autonomy; Convenience; End of life care; Satisfaction; Willingness to pay

Indexed keywords

INDACATEROL; NARCOTIC ANALGESIC AGENT; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT;

AROUSAL; ARTIFICIAL VENTILATION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG PREFERENCE; DRY POWDER INHALER; DYSPNEA; HEALTH STATUS; HUMAN; INHALER; MECHANICAL VENTILATOR; METERED DOSE INHALER; NONINVASIVE VENTILATION; PATIENT AUTONOMY; PATIENT DECISION MAKING; PATIENT PREFERENCE; PATIENT SATISFACTION; QUALITY OF LIFE; RESUSCITATION; REVIEW; SOFT MIST INHALER; TERMINAL CARE; ACCESS TO INFORMATION; COST OF ILLNESS; DAILY LIFE ACTIVITY; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; NEBULIZER; PATHOPHYSIOLOGY; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACCESS TO INFORMATION; ACTIVITIES OF DAILY LIVING; ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; COST OF ILLNESS; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PATIENT PREFERENCE; PHYSICIAN-PATIENT RELATIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TERMINAL CARE; TREATMENT OUTCOME;

EID: 84929413123     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S82179     Document Type: Review

References (45)

1. Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11:404–406.
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1,160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–2196.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
4. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223.
5. NICE. Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence. NICE Clinical Guideline 76; 2009. Available from: http://www.nice.org.uk/guidance/cg76/resources/guidance-medicines-adherence-pdf
6. Wennberg JE, Barry MJ, Fowler FJ, Mulley A. Outcomes research, PORTs, and health care reform. Ann N Y Acad Sci. 1993;703:52–62.
7. Torgerson DJ, Sibbald B. Understanding controlled trials. What is a patient preference trial? BMJ. 1998;316:360.
8. Brewin CR, Bradley C. Patient preferences and randomised clinical trials. BMJ. 1989;299:313–315.
9. Serra-Batlles J, Plaza V, Morejón E, Comella A, Brugués J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12:1322–1326.
10. Gonzalez-Barcala FJ, De la Fuente-Cid R, Tafalla M, Nuevo J, Caamaño-Isorna F. Factors associated with health-related quality of life in adults with asthma. A cross-sectional study. Multidiscip Respir Med. 2012;7:32.
11. Weldam SW, Lammers JW, Heijmans MJ, Schuurmans MJ. Perceived quality of life in chronic obstructive pulmonary disease patients: a cross-sectional study in primary care on the role of illness perceptions. BMC Fam Pract. 2014;14:140.
12. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2010; 2010. Available from: www.ginasthma.org/pdf/GINA_report_2010.pdf. [Updated 2012]. Accessed February 1, 2015.
13. Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management and Prevention, 2011; 2011. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Pocket_May2512.pdf. Accessed February 1, 2015.
14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
15. Bulcun E, Ekici M, Ekici A. Assessment of patients’ preferences regarding the characteristics associated with the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:363–368.
16. Haughney J, Partridge MR, Vogelmeier C, et al. Exacerbations of COPD: quantifying the patient’s perspective using discrete choice modelling. Eur Respir J. 2005;26:623–629.
17. Pisa G, Freytag S, Schandry R. Chronic obstructive pulmonary disease (COPD) patients’ disease-related preferences: a study using conjoint analysis. Patient. 2013;6:93–101.
18. Rocker GM, Dodek PM, Heyland DK; Canadian Researchers at the End of Life Network. Toward optimal end-of-life care for patients with advanced chronic obstructive pulmonary disease: insights from a multicentre study. Can Respir J. 2008;15:249–254.
19. Jordan P, Quadrelli S, Heres M, Belli L, Ruhl N, Colt H. Examining patients’ preferences for participation in clinical decision-making: the experience in a Latin American chronic obstructive pulmonary disease and cancer outpatient population. Intern Med J. 2014;44:281–287.
20. Goossens LM, Utens CM, Smeenk FW, Donkers B, van Schayck OC, Rutten-van Mölken MP. Should I stay or should I go home? A latent class analysis of a discrete choice experiment on hospital-at-home. Value Health. 2014;17:588–596.
21. Utens CM, Goossens LM, van Schayck OC, et al. Patient preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: results of a randomised controlled trial. Int J Nurs Stud. 2013;50:1537–1549.
22. Beier J, Kirsten AM, Mróz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013;10:511–522.
23. Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353–363.
24. Ferguson GT, Ghafouri M, Dai L, Dunn LJ. COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study. Int J Chron Obstruct Pulmon Dis. 2013;8:139–150.
25. Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences. Int J Chron Obstruct Pulmon Dis. 2014;9:107–114.
26. Van Der Palen J, Ginko T, Kroker A, et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv. 2013;10:1023–1031.
27. Rocker GM, Simpson AC, Joanne Young BHSC, et al. Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients’ experiences and outcomes. CMAJ Open. 2013;1:E27–E36.
28. Chakrabarti B, Sulaiman MI, Davies L, Calverley PM, Warburton CJ, Angus RM. A study of patient attitudes in the United Kingdom toward ventilatory support in chronic obstructive pulmonary disease. J Palliat Med. 2009;12:1029–1035.
29. Dales RE, O’Connor A, Hebert P, Sullivan K, McKim D, Llewellyn-Thomas H. Intubation and mechanical ventilation for COPD: development of an instrument to elicit patient preferences. Chest. 1999;116:792–800.
30. Downey L, Au DH, Curtis JR, Engelberg RA. Life-sustaining treatment preferences: matches and mismatches between patients’ preferences and clinicians’ perceptions. J Pain Symptom Manage. 2013;46:9–19.
31. Gaber KA, Barnett M, Planchant Y, McGavin CR. Attitudes of 100 patients with chronic obstructive pulmonary disease to artificial ventilation and cardiopulmonary resuscitation. Palliat Med. 2004;18:626–629.
32. Janssen DJ, Spruit MA, Schols JM, et al. Predicting changes in preferences for life-sustaining treatment among patients with advanced chronic organ failure. Chest. 2012;141:1251–1259.
33. Norris WM, Nielsen EL, Engelberg RA, Curtis JR. Treatment preferences for resuscitation and critical care among homeless persons. Chest. 2005;127:2180–2187.
34. Reinke LF, Slatore CG, Udris EM, Moss BR, Johnson EA, Au DH. The association of depression and preferences for life-sustaining treatments in veterans with chronic obstructive pulmonary disease. J Pain Symptom Manage. 2011;41:402–411.
35. Stapleton RD, Nielsen EL, Engelberg RA, Patrick DL, Curtis JR. Association of depression and life-sustaining treatment preferences in patients with COPD. Chest. 2005;127:328–334.
36. Travaline JM, Silverman HJ. Discussions with outpatients with chronic obstructive pulmonary disease regarding mechanical ventilation as life-sustaining therapy. South Med J. 1995;88:1034–1038.
37. Wilson KG, Aaron SD, Vandemheen KL, et al. Evaluation of a decision aid for making choices about intubation and mechanical ventilation in chronic obstructive pulmonary disease. Patient Educ Couns. 2005;57: 88–95.
38. Stavem K. Association of willingness to pay with severity of chronic obstructive pulmonary disease, health status and other preference measures. Int J Tuberc Lung Dis. 2002;6:542–549.
39. Janssen DJ, Spruit MA, Schols JM, Wouters EF. Dynamic preferences for site of death among patients with advanced chronic obstructive pulmonary disease, chronic heart failure, or chronic renal failure. J Pain Symptom Manage. 2013;46:826–836.
40. Adams RJ, Smith BJ, Ruffin RE. Patient preferences for autonomy in decision making asthma management. Thorax. 2001;56:126–132.
41. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004;23:723–729.
42. Hodder R, Reese PR, Slaton T. Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:225–232.
43. Lloyd A, Doyle S, Dewilde S, Turk F. Preferences and utilities for the symptoms of moderate to severe allergic asthma. Eur J Health Econ. 2008;9:275–284.
44. McTaggart-Cowan HM, Shi P, Fitzgerald JM, et al. An evaluation of patients’ willingness to trade symptom-free days for asthma related treatment risks: a discrete choice experiment. J Asthma. 2008;45:630–638.
45. Lloyd A, McIntosh E, Williams AE, Kaptein A, Rabe KF. How does patients’ quality of life guide their preferences regarding aspects of asthma therapy?: a patient-preference study using discrete-choice experiment methodology. Patient. 2008;1:309–316.